RESUMEN
This parallel-group study compared the safety and efficacy of controlled-release albuterol versus sustained-release theophylline, both administered every 12 hours. One hundred twenty-four adolescent and adult patients with asthma and with chronic reversible obstructive airway disease were studied. All patients qualified with an FEV1 less than or equal to 80% of predicted (not receiving treatment) and greater than or equal to 15% reversibility in FEV1 or greater than or equal to 25% reversibility in FEF25-75% after inhaled isoproterenol. All patients were known to be able to take theophylline without unacceptable adverse effects. Theophylline was titrated for patients to receive, unblinded, theophylline serum concentrations of 10 to 20 micrograms/ml. With subsequent randomization, 62 patients continued to receive theophylline and 62 patients started taking albuterol in the 12-week, double-blind, double-dummy portion of the study. Pulmonary function was measured during a pretreatment visit (unmedicated) and serial assessment was made starting just before the morning dose and continuing for 12 hours after the dose at the end of 1, 6, and 12 weeks of treatment. Both treatment groups exhibited statistically significant increases in FEV1 from the pretreatment visit to all times of observation at weeks 1, 6, and 12. The increases in FEV1 were not significantly different between albuterol and theophylline administration. There was no evidence of tolerance to the bronchodilatory effect during 12 weeks in either treatment group. Only one patient in the study stopped treatment because of an adverse effect. This patient had tremor during albuterol administration. All other adverse events were tolerated or resolved during treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Albuterol/administración & dosificación , Asma/tratamiento farmacológico , Teofilina/administración & dosificación , Adolescente , Adulto , Albuterol/efectos adversos , Albuterol/sangre , Asma/sangre , Asma/fisiopatología , Cápsulas , Preparaciones de Acción Retardada , Método Doble Ciego , Humanos , Ápice del Flujo Espiratorio/efectos de los fármacos , Ápice del Flujo Espiratorio/fisiología , Ensayos Clínicos Controlados Aleatorios como Asunto , Comprimidos , Teofilina/efectos adversos , Teofilina/sangre , Factores de TiempoRESUMEN
Antihypertensive medications currently used in the treatment of hypertensive urgencies are limited due to deleterious side effects or requirements for sophisticated monitoring techniques. Labetalol HCl (Trandate) is a unique adrenergic blocking agent that can smoothly lower blood pressure following bolus injection without increasing heart rate or cardiac output. This study evaluates the efficacy and safety of intravenous boluses of labetalol HCl in the treatment of patients presenting to the hospital with a diagnosis of hypertensive urgency (diastolic blood pressure greater than or equal to 110 mm Hg). After baseline blood pressure and heart rate were recorded, 20 consecutive patients were treated with an initial 20-mg bolus of labetalol. Additional boluses of 40, 80, and 160 mg were administered at least 10 minutes apart in a step-wise fashion until control of blood pressure (diastolic blood pressure less than 100 mm Hg) was achieved or a total of 300 mg had been given. Blood pressures and heart rates were recorded at the time of response or following the last dose of labetalol. Mean (+/- SEM) supine systolic blood pressure decreased from 185 +/- 3 to 155 +/- 4 mm Hg (P less than 0.05) following labetalol therapy, and mean supine diastolic pressure decreased from 120 +/- 2 to 98 +/- 2 mm Hg (P less than 0.05). Mean heart rate did not change significantly. Eighteen of the 20 patients exhibited a therapeutic response; nine patients received a total of 20 mg, six required 60 mg, two required 140 mg, one received 300 mg. Of the two patients who did not respond, one received the maximum dose (300 mg).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Hipertensión/tratamiento farmacológico , Labetalol/uso terapéutico , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/fisiopatología , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
The hemodynamic effects of esmolol were evaluated in 12 male patients at rest (mean age, 51 +/- 10 years) undergoing routine cardiac catheterization. Hemodynamic measurements were obtained during baseline (prior to esmolol), at steady state (during an intravenous infusion of esmolol 300 micrograms/kg/min), and at 30 minutes after stopping esmolol (postinfusion). Esmolol produced hemodynamic effects similar to the effects of other beta blockers. Significant reductions in rate-pressure product (mean decrease, 15%), cardiac index (mean decrease, 17%), stroke volume index (mean decrease, 13%), left ventricular stroke work index (mean decrease, 20%), and left ventricular ejection fraction (mean decrease, 18%) were observed. In contrast to other beta blockers, all hemodynamic effects of esmolol had returned to baseline values within 30 minutes after the infusion stopped. One patient exhibited hypotension during the esmolol infusion; this episode resolved without sequelae after discontinuation of esmolol. In summary, the effects of esmolol at rest on hemodynamic parameters and left ventricular function are similar to other beta-adrenergic blocking agents. Due to its ultrashort half-life, esmolol can be administered safely in critically ill patients whose disease status makes treatment with currently available beta blockers risky.
Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Enfermedad Coronaria/fisiopatología , Hemodinámica/efectos de los fármacos , Propanolaminas/farmacología , Antagonistas Adrenérgicos beta/efectos adversos , Antagonistas Adrenérgicos beta/sangre , Adulto , Presión Sanguínea/efectos de los fármacos , Pruebas de Función Cardíaca , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Propanolaminas/efectos adversos , Propanolaminas/sangreRESUMEN
Initial experience with one strategy to modify selection of empiric antibiotic therapy by medical residents in presented. New orders for parenteral antibiotics written by residents before receiving culture results were randomly allocated to either a recommendation or a control group. Antibiotic orders from each group were compared with guidelines for antibiotic selection, and suggestions to change antibiotics were made only for orders from the recommendation group that did not match the guidelines. Recommendations for change appeared necessary for about 20% of the orders within each group. At follow-up, 78% of these orders had been changed as suggested in the recommendation group, whereas only 10% of the orders in the control group were changed (p less than 0.005). The mean difference in daily cost per order was a savings of $27.40 in the recommendation group and only $1.11 in the control group (p less than 0.01).